North China Pharmaceutical’s penalty for the suspension of supply is a response from the Fermentation United Procurement Agency

On August 24, the National Organization for Pharmaceutical Joint Purchasing Office responded to the punishment of North China Pharmaceutical for the suspension of supply, and answered the key concerns of the industry

The original text is as follows:

Recently, because North China Pharmaceutical Co.

1.

2.

(1) Facts of breach of contract

(2) Basis for processing

(3) Follow-up impact

3.

The state organizes centralized drug procurement to adhere to the decisive role of the market in price formation.

There are 4 selected companies for ibuprofen sustained-release capsules.

4.

In addition, it needs to be pointed out that the room for price reduction of centralized procurement mainly comes from three aspects, including direct supply to hospitals to reduce marketing costs, timely collection of funds to reduce financial costs, and small profits but quick turnover to reduce production costs.

5.
What are the considerations for the next reform of centralized procurement? How to ensure the supply of selected products?

Answer: In accordance with the deployment of the Party Central Committee and the State Council, we will unswervingly deepen the reform of centralized procurement of pharmaceuticals and at the same time further improve the centralized procurement rules and supporting measures to ensure the supply of selected products
.
In the past few batches of centralized procurement, we have gradually increased the number of selected companies through optimizing the rules and strengthened the supply guarantee.
In the next step, we will further improve the following measures
.

One is to strengthen the monitoring and handling of the supply of selected drugs
.
Further clarify the responsibility of enterprises for supply performance, implement the "Opinions of the General Office of the State Council on Promoting the Normalized and Institutionalized Development of Centralized and Volumetric Procurement of Drugs" (Guobanfa [2021] No.
2), and require selected enterprises to do a good job in predicting and preventing market risks , Organize production and supply in accordance with the procurement contract to meet the procurement needs of selected drugs
.
The Joint Procurement Office will strengthen the monitoring and early warning of the procurement of the selected products, and deal with the problems found in the procurement process such as the failure of the company to perform the supply agreement
.
At the same time, the provinces will also actively perform their duties and perform their duties.
According to the National Medical Insurance Administration's "Guiding Opinions on Establishing a Credit Evaluation System for Pharmaceutical Prices and Recruitment and Procurement", the main responsibility of the selected enterprises for performance of the contract will be compacted through credit evaluation, and for the enterprises that cannot perform after the election.
Give a rating of untrustworthiness and make corresponding actions
.

The second is to effectively strengthen the application of violation lists and untrustworthy ratings in the field of centralized drug procurement
.
Strengthen the use of violations and untrustworthy results, and further restrict the violation and untrustworthy enterprises in the future national and provincial centralized procurement declaration conditions
.
When carrying out the continuation of the expiration of the centralized procurement agreement, strengthen the weight of supply and credit in the process of generating the selected enterprises, so that the trustworthy will be more likely to be selected, and the untrustworthy will be restricted
.

The third is to implement alternative mechanisms to improve market supply stability
.
The relevant documents of the national organization of the centralized drug procurement have been clarified.
When the selected company cannot supply the procurement needs of medical institutions in a timely manner, the province can initiate the selection process of the candidate company to ensure sufficient clinical supply and reasonable prices
.
After North China Pharmaceutical applied for abandoning the qualification, the Shandong Provincial Medical Insurance Department immediately initiated the candidate enterprise procedure.
According to the established selection procedure, Zhuhai Rundu Pharmaceutical Co.
, Ltd.
has been determined as a substitute enterprise to supply Shandong Province, and according to Zhuhai Rundu Pharmaceutical’s national organization The selected price is 4.
05 yuan per box (20 tablets), which is lower than the selected price of North China Pharmaceuticals.
Patients in Shandong Province will purchase drugs that have also passed the consistency evaluation at a lower price
.